Chicago Capital LLC Cuts Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Chicago Capital LLC cut its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 29.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 102,171 shares of the medical research company’s stock after selling 42,395 shares during the period. Chicago Capital LLC’s holdings in Edwards Lifesciences were worth $6,742,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Edwards Lifesciences by 1.1% during the first quarter. Vanguard Group Inc. now owns 52,964,394 shares of the medical research company’s stock valued at $5,061,277,000 after purchasing an additional 600,994 shares in the last quarter. Bank of New York Mellon Corp grew its position in Edwards Lifesciences by 4.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock worth $1,827,347,000 after purchasing an additional 809,605 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Edwards Lifesciences by 57.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock worth $622,695,000 after buying an additional 2,390,137 shares in the last quarter. Champlain Investment Partners LLC boosted its stake in shares of Edwards Lifesciences by 3.1% in the 1st quarter. Champlain Investment Partners LLC now owns 2,964,168 shares of the medical research company’s stock worth $283,256,000 after buying an additional 88,205 shares during the last quarter. Finally, AustralianSuper Pty Ltd grew its holdings in shares of Edwards Lifesciences by 14.2% in the second quarter. AustralianSuper Pty Ltd now owns 2,778,812 shares of the medical research company’s stock valued at $256,679,000 after acquiring an additional 344,465 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares in the company, valued at $2,051,843.35. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,101,530.88. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 16,250 shares of company stock valued at $1,099,238 in the last three months. Company insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

EW has been the topic of a number of recent analyst reports. Canaccord Genuity Group dropped their price target on Edwards Lifesciences from $77.00 to $66.00 and set a “hold” rating on the stock in a report on Monday, October 7th. Daiwa Capital Markets upgraded Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 31st. TD Cowen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their price target for the company from $100.00 to $70.00 in a research report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, July 25th. Finally, JPMorgan Chase & Co. cut shares of Edwards Lifesciences from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $105.00 to $72.00 in a research note on Thursday, July 25th. Fifteen analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $75.81.

Edwards Lifesciences Stock Up 2.6 %

Shares of NYSE EW opened at $70.27 on Friday. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. The company has a market cap of $42.34 billion, a P/E ratio of 30.29, a P/E/G ratio of 2.83 and a beta of 1.13. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The business has a 50-day simple moving average of $67.81 and a two-hundred day simple moving average of $79.18.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. The firm had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.66 earnings per share. Research analysts anticipate that Edwards Lifesciences Co. will post 2.71 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.